Osimertinib (dimesylate)

Osimertinib (dimesylate)

• CAS Number: 2070014-82-1
• UNSPSC Description: Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
• Target Antigen: EGFR
• Type: Reference compound
• Related Pathways: JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/AZD-9291-dimesylate.html
• Purity: 99.96
• Solubility: DMSO : 2.63 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
• Smiles: CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
• Molecular Weight: 691.82
• References & Citations: [1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.|[2]Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistancemutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67.Research Square Preprint. 2021 May.|ACS Nano. 2022 Jul 21.|Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. |Acta Pharmacol Sin. 2021 Jan 7.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Sci (Weinh). 2024 May 2:e2306348.|Adv Ther. 2024 Jul 18.|Am J Cancer Res. 2023 Sep 15;13(9):4145-4162.|Am J Transl Res. 2021 Jun 15;13(6):6055-6065.|Anticancer Res. 2024 Oct;44(10):4175-4188.|Anticancer Res. 2019 Sep;39(9):4817-4828.|Appl Surf Sci. 2024 Dec 21.|Biochem Biophys Res Commun. 2024 Sep 19:733:150711.|Biomed Pharmacother. 2024 Jan 9:171:116124.|Bioorg Chem. 2023 Mar 27.|bioRxiv. 2023 Oct 27.|bioRxiv. 2024 Feb 12.|Cancer Cell Int. 2021 Apr 15;21(1):216.|Cancer Cell Int. 2021 Jul 3;21(1):337.|Cancer Discov. 2019 Jul;9(7):926-943.|Cancer Gene Ther. 2022 Sep 19.|Cancer Res Treat. 2023 Jan 26.|Cancer Res. 2023 Apr 16;CAN-22-3059.|Cancer Res. 2023 Dec 14.|Cancer Res. 2023 May 2;83(9):1490-1502.|Cancers. 2019 Jul 5;11(7):947.|Cancers. 2019 Oct 14;11(10):1550.|Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.|Cell Death Differ. 2024 May 30.|Cell Death Dis. 2019 Aug 13;10(8):615.|Cell Death Dis. 2019 May 1;10(5):361. |Cell Oncol. 2022 Sep 21.|Cell Rep Med. 2023 Jan 10;100911.|Cell Rep Med. 2024 Mar 19;5(3):101471.|Cell Rep. 2024 Oct 8;43(10):114812.|Commun Biol. 2021 Dec 13;4(1):1391.|Drug Deliv Transl Res. 2021 Nov 23.|Drug Metab Pharmacokinet. 2020 Oct;35(5):456-465.|Environ Toxicol. 2019 Apr;34(4):476-485. |Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.|Eur J Pharmacol. 2021, 174297.|Exp Hematol Oncol. 2024 Oct 1;13(1):97.|Faculty of Medicine. University of Oslo. 2019 Feb.|Fundam Clin Pharmacol. 2021 Feb 1.|Genes Cancer. 2017 Mar;8(3-4):497-504.|Int Immunopharmacol. 2023 Nov 23:126:111265.|Int J Anal Chem. 2020 Dec 29.|Int J Biol Macromol. 2024 May;268(Pt 1):131560.|Int J Biol Sci. 2021; 17(7):1671-1681.|Int J Mol Med. 2023 Nov;52(5):102.|Int J Mol Sci. 2023 May 15, 24(10), 8794.|Int J Oncol. 2020 Jan;56(1):243-257.|J Biol Chem. 2023 May 11;104814.|J Cell Physiol. 2021 Nov 21.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.|J Control Release. 2024 Nov 5:376:829-841.|J Ethnopharmacol. 2024 Jul 18:118586.|J Exp Clin Cancer Res. 2019 Mar 15;38(1):129.|J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. |J Exp Clin Cancer Res. 2019 May 23;38(1):219. |J Med Chem. 2017 Apr 13;60(7):2944-2962. |J Med Chem. 2023 Apr 11.|J Nat Med. 2023 Apr 12.|J Natl Cancer Inst. 2023 Jul 22;djad142.|J Pharm Anal. 2021 Jun 19.|Mol Cancer Res. 2019 Feb;17(2):499-507. |Mol Cancer Res. 2019 Nov;17(11):2233-2243.|Mol Cancer Res. 2024 Jul 2.|Mol Cancer Ther. 2018 Mar;17(3):603-613.|Mol Cancer Ther. 2019 May;18(5):920-928.|Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027.|Mol Med Rep. 2021 Jan;23(1):48.|Mol Oncol. 2023 Apr 4.|Mol Pharmacol. April 5, 2022.|Nat Cancer. 2022 Apr;3(4):402-417.|Nat Cancer. 2023 Jun;4(6):829-843.|Neoplasia. 2024 Aug 14:57:101039.|Oncogene. 2022 May;41(22):3104-3117.|Oncogene. 2024 Aug 15.|Oncogene. 2024 Oct 14.|Oncol Lett. 2023 Jul 20.|Oncotarget. 2015 Oct 13;6(31):31313-22. |Oncotarget. 2016 Oct 25;7(43):69760-69769.|Oncotarget. 2017 Mar 14;8(11):18359-18372. |Patent. US20190010159A1.|Patent. US20200276189A1.|Patent. US20210315911A1.|Patent. US20230158019A1.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Mar.|Research Square Preprint. 2021 May.|Research Square Preprint. 2023 May 5.|Research Square Preprint. 2024 Jan 3.|Research Square Preprint. 2024 Nov 26.|Research Square Print. December 21st, 2022.|Respir Physiol Neurobiol. 2020 Oct;281:103496.|Respir Res. 2024 May 20;25(1):215.|RSC Chem Biol. 2023 Aug 29.|Theranostics. 2021 Jan 19;11(7):3392-3416.|Theranostics. 2021 Mar 24;11(12):5650-5674.|Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712.|Universitat Politècnica de València. 2021 Sep.|Cancer Cell. 2020 Jan 13;37(1):104-122.e12.|Cancer Lett. 2023 May 19;216237.|Commun Biol. 2024 Mar 1;7(1):250.|Int J Electrochem Sci. 2024 Nov 26.|Oncotarget. 2017 Dec 6;9(2):1641-1655.|Research Square Preprint. 2023 Jun 30.|Xenobiotica. 2018 Nov;48(11):1106-1112.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched